Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients
Publication

Publications

Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients

Title
Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients
Type
Article in International Scientific Journal
Year
2020-01-23
Authors
Paulo Linhares
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Journal
Vol. 147
Pages: 109-116
ISSN: 0167-594X
Publisher: Springer Nature
Other information
Authenticus ID: P-00R-NFV
Abstract (EN): Introduction Arterial hypertension and proteinuria are common side effects of antiangiogenic treatment and might represent a biomarker of response in patients with glioblastoma. The aim of this study was to assess the impact of these side effects in predicting therapeutic response to second line chemotherapy with bevacizumab. Methods We evaluated clinical and survival data of glioblastoma patients who underwent treatment with bevacizumab after progression under temozolomide, at CHUSJ between 2010 and 2017. We analysed treatment-related arterial hypertension, proteinuria grade, thrombotic and haemorrhagic events during treatment. Overall survival (OS) and progression free survival (PFS) under bevacizumab were calculated according to the Kaplan-Meier method. Multivariate analysis was performed using Cox proportional hazards method. Results We evaluated 140 patients. Arterial hypertension and proteinuria occurred in 23 (16.3%) and 17 (12.1%) patients, respectively. PFS during treatment with bevacizumab was 12 months (95% CI 7.9-16.1) in the hypertensive group and 4 months (95% CI 3.2-4.8) in the normotensive group (p = 0.005). Patients with proteinuria had a PFS of 10 months (95% CI 4.9-15.0) versus 4 months (95% CI 3.4-4.8) in patients without proteinuria (p = 0.002). Multivariate analysis revealed hypertension and proteinuria as independent prognostic factors of PFS and OS. Conclusion Our data suggest that hypertension and proteinuria can be effective predictors of response to antiangiogenic therapy in recurrent glioblastoma and are associated with longer disease control.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 8
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same authors

The importance of the neutrophil-to-lymphocyte ratio in the prognosis of glioma and its subtypes (2020)
Another Publication in an International Scientific Journal
Paulo Linhares
Glioblastoma: Is There Any Blood Biomarker with True Clinical Relevance? (2020)
Another Publication in an International Scientific Journal
Paulo Linhares
Early deep brain stimulation in patients with myoclonus-dystonia syndrome (2016)
Another Publication in an International Scientific Journal
Paulo Linhares
Survival Determinants in Glioblastoma: An Insight into Biopsy-Only Patient Outcomes (2024)
Other Publications
Gonçalves, JM; Ferreira, F; Carvalho, B; Polónia, P; Linhares, P
Sequential Evaluation of Hematology Markers as a Prognostic Factor in Glioblastoma Patients (2024)
Other Publications
Gonçalves, JM; Carvalho, B; Tuna, R; Polónia, P; Linhares, P

See all (45)

Of the same journal

Reversion of phenotype of endothelial cells in brain tissue around glioblastomas (1996)
Article in International Scientific Journal
Vaz, R; Borges, Nuno; Sarmento A; Azevedo, I
PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma (2022)
Article in International Scientific Journal
Noronha, C; Ribeiro, AS; Taipa, R; Leitao, D; Fernando Schmitt; Reis, J; Faria, C; Paredes, J
Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme (2018)
Article in International Scientific Journal
Paulo Linhares
Giant skull metastasis of Hurthle cell variant of thyroid's papillary carcinoma (2008)
Article in International Scientific Journal
Mendes, VC; Linhares, P; Fonseca E; Ribeiro Silva, ML
EGF genetic polymorphism is associated with clinical features but not malignant phenotype in neurofibromatosis type 1 patients (2007)
Article in International Scientific Journal
Ricardo Ribeiro; Angelo Soares; Daniela Pinto; Raquel Catarino; Carlos Lopes; Rui Medeiros

See all (7)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-08-06 at 17:25:04 | Privacy Policy | Personal Data Protection Policy | Whistleblowing